5 results about "Advanced breast" patented technology

This invention discloses the application of ethinylestradiol and drospirenone in the preparation of drugs for treating post-traumatic stress disorder (PTSD). Ethinylestradiol, as an estrogen receptor agonist, regulates the hypothalamic-pituitary-gonadal axis and is used to treat female hypogonadism, menopausal syndrome, and advanced breast cancer, often in combination with progestins as oral contraceptives. The use of drospirenone and ethinylestradiol tablets (II) after induced abortion can shorten vaginal bleeding time, promote endometrial repair, and reduce the incidence of postoperative complications and repeat miscarriages. This invention has found that ethinylestradiol and drospirenone can reverse the abnormal decrease in hormones and neurosteroids caused by PTSD after spontaneous abortion, particularly the abnormal decrease in serotonin and tetrahydroprogesterone.

The present invention provides a topoisomerase I / II dual-target inhibitor, its preparation method, and application, belonging to the field of medicine. The present invention uses 6-bromopiperonal as a raw material to synthesize a compound having a structural formula as shown in Formula I. This compound is a novel topoisomerase I / II dual-target inhibitor that can be used to treat diseases such as small cell lung cancer, advanced metastatic ovarian cancer, advanced breast cancer, colorectal cancer, and bladder cancer, and has good application prospects.

The invention provides a diagnostic reagent and method for early discovery of breast nodules based on serum GRP detection. The reagent comprises a GRP standard substance, a GRP primary antibody, a buffer solution, a developing solution and a stop solution, the GRP level in serum is detected through enzyme-linked immunosorbent assay (ELISA), and the reagent is used for screening breast benign nodules and early breast cancer. By collecting a serum sample, detecting the GRP concentration and comparing the GRP concentration with a healthy control group, existence of breast nodules is judged, and the kit has high sensitivity and specificity, is particularly suitable for early-stage cases without obvious anomalies in imaging, and provides an efficient tool for non-invasive diagnosis of breast diseases. The diagnostic reagent is easy and convenient to operate, short in detection time and suitable for clinical large-scale screening, the method is combined with correlation analysis of the GRP level and the nodule volume, benign nodules, early breast cancer and advanced breast cancer can be effectively distinguished, a basis is provided for disease prognosis evaluation, the accuracy of early discovery of breast nodules is remarkably improved, and the clinical application prospect is wide. And an important reference is provided for formulating a treatment scheme.

The present disclosure relates to methods of increasing time to second progression or death and time to first subsequent chemotherapy in subjects having advanced breast cancer using therapeutic combinations of capivasertib and fulvestrant.

The application discloses a preparation method of an intermediate of a breast cancer treatment drug Irla group, which comprises the following steps: in step 1, 6-hydroxy-3,4-dihydro-1H-2-naphthalenone is first subjected to hydroxyl silylation protection, then subjected to C-C coupling docking reaction with trimethylchlorosilane, and finally subjected to deprotection to obtain the intermediate 2-(4-methoxy-2-nitrophenyl)-1,2,3,4-tetrahydronaphthalene-2,6-diol; in step 2, the product in step 1 is subjected to dehydroxylation reaction to obtain the intermediate 6-(4-methoxy-2-nitrophenyl)-5,6,7,8-tetrahydronaphthalen-2-ol; and in step 3, the product in step 2 is subjected to nitro reduction reaction to obtain 6-(2-amino-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol. The new synthesis method of the Irla group has the obvious advantages over the prior art, the reaction is complete, and the by-products are less.